OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration. In this programme, Exscientia has designed a novel lead series with a potential best in class profile, with preliminary data showing good potency and selectivity towards the target and differentiated molecular properties..

英国牛津——（商业新闻短讯）——Exscientia plc（纳斯达克：EXAI）今天宣布，赛诺菲正在将Exscientia确定并初步推进的新发现阶段计划添加到当前的合作中。在这个项目中，Exscientia设计了一个新的铅系列，具有潜在的同类最佳概况，初步数据显示出对目标和差异化分子特性的良好效力和选择性。。

“Sanofi adding an Exscientia discovery stage programme into the collaboration speaks to the strengths of our AI-driven platform to solve complex drug discovery problems,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia. “The growth of our collaboration is a testament to our strong relationship with Sanofi and our shared vision for AI-enabled drug discovery.

Exscientia创始人兼首席执行官安德鲁·霍普金斯教授（AndrewHopkins FRS FMedSci）表示：“赛诺菲（Sanofi）在合作中加入了Exscientia发现阶段计划，说明了我们人工智能驱动平台在解决复杂药物发现问题方面的优势。”。“我们合作的增长证明了我们与赛诺菲的牢固关系以及我们对人工智能药物发现的共同愿景。

As we enter 2024, we expect to continue working with partners to apply our platform capabilities across therapeutic areas while maintaining our internal pipeline focus on high value oncology targets.”.

随着我们进入2024年，我们预计将继续与合作伙伴合作，在治疗领域应用我们的平台功能，同时保持我们的内部管道专注于高价值肿瘤学目标。”。

Under the terms of the amended agreement, Exscientia is eligible for up to $45 million in upfront and preclinical milestone payments. Exscientia will also be eligible for additional development, regulatory and sales-based milestone payments of over $300 million and tiered royalties on product sales ranging from high-single-digits to mid-teens, as described in the original collaboration agreement.

根据修订后的协议条款，Exscientia有资格获得高达4500万美元的预付款和临床前里程碑付款。Exscientia还将有资格获得额外的开发、监管和基于销售的里程碑付款，金额超过3亿美元，以及产品销售的分层版税，从高个位数到十几岁，如原始合作协议所述。

The upfront payment is expected to be reflected in the first quarter 2024 results for Exscientia as cash inflows from collaborations and recognised as revenue over the duration of the agreement..

预付款预计将反映在Exscientia 2024年第一季度的业绩中，作为合作产生的现金流入，并在协议期间确认为收入。。

About Exscientia

关于Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting.

Exscientia是一家人工智能驱动的精准医学公司，致力于以最快和最有效的方式发现，设计和开发尽可能最好的药物。Exscientia开发了有史以来第一个功能精确肿瘤学平台，以在前瞻性介入临床研究中成功指导治疗选择并改善患者预后，并将人工智能设计的小分子推进临床环境。

Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients..

我们的内部渠道专注于利用我们在肿瘤学领域的精准医学平台，而我们的合作渠道将我们的方法扩展到其他治疗领域。通过开创医学创新的新方法，我们相信最好的科学思想可以迅速成为患者的最佳药物。。

Visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.

请访问www.exscientia.ai或在推特@exccientiaAI上关注我们。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules. Any statement describing Exscientia’s goals, plans, expectations, projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.

本新闻稿包含前瞻性声明，该术语在1995年《私人证券诉讼改革法案》中有定义，包括候选分子的发现和开发进展。任何描述Exscientia目标、计划、期望、预测、意图或信念的声明都是前瞻性声明，应视为有风险的声明。

Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates.

这些声明受到许多风险、不确定性和假设的影响，包括与发现、开发和商业化候选产品过程有关的风险、不确定性和假设，这些候选产品安全有效地用作人类治疗药物；以及围绕这些候选产品建立业务的努力。

In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby.

鉴于这些风险和不确定性，以及Exscientia于2022年3月23日向美国证券交易委员会（SEC）提交的表20-F年度报告（文件号001-40850）中风险因素部分和其他部分中描述的其他风险和不确定性，以及Exscientia不时向SEC提交的其他文件（可在https://www.sec.gov/)，此类前瞻性声明中讨论的事件和情况可能不会发生，Exscientia的实际结果可能与预期或暗示的结果存在重大不利差异。

Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements..

虽然Exscientia的前瞻性陈述反映了其管理层的诚信判断，但这些陈述仅基于公司目前已知的事实和因素。因此，请注意不要依赖这些前瞻性声明。。